Nov 20, 2019 / 04:00PM GMT
David Michael Steinberg - Jefferies LLC, Research Division - Specialty Pharma Analyst & Equity Analyst
Good afternoon, everyone. We're delighted to have with us from sunny Northern California, Nektar Therapeutics. And we have with us Jonathan Zalevsky, also known as JZ, who just got his title upgraded to Head of Research and Development, or Global Head of Research and Development.
Jonathan Zalevsky - Nektar Therapeutics - Chief Research & Development Officer
Thank you, David. Thank you very much, everyone. I appreciate your attention, and I'd like to thank the meeting organizers for the opportunity to present. Here today, I'll be making some forward-looking statements. The most recent information about Nektar is available in our Form 10-Q, which was filed in November of this year.
Well, at Nektar, our core strength is polymer chemistry. And we've been applying polymer chemistry to a whole range of products that have entered into the marketplace, going all the way back to products like pegylated interferon, antibodies like CIMZIA, and most
Nektar Therapeutics at Jefferies London Healthcare Conference Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers